Phase II trials - endpoints, when to randomize

被引：0
|
作者：
Zee, Benny [1 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2007年 / 2卷 / 08期
关键词：
D O I：
10.1097/01.JTO.0000283066.47583.94
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [1] Endpoints for Phase II Trials
    Chang, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S40 - S40
  • [2] Examining endpoints for phase II clinical trials
    Sznol, Mario
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, 7 (12) : 1042 - 1043
  • [3] Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors
    Imaoka, Hiroshi
    Sasaki, Mitsuhito
    Takahashi, Hideaki
    Hashimoto, Yusuke
    Ohno, Izumi
    Mitsunaga, Shuichi
    Watanabe, Kazuo
    Umemoto, Kumiko
    Kimura, Gen
    Suzuki, Yuko
    Kan, Motoyasu
    Ikeda, Masafumi
    ONCOLOGIST, 2019, 24 (01): : 47 - 53
  • [4] Trials which randomize practices II: sample size
    Kerry, SM
    Bland, JM
    FAMILY PRACTICE, 1998, 15 (01) : 84 - 87
  • [5] WHEN TO RANDOMIZE
    DURRLEMAN, S
    SIMON, R
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (01) : 116 - 122
  • [6] Efficacy Endpoints in Phase II Clinical Trials for Meningioma: An Analysis of Recent Clinical Trials
    Watanabe, Shinya
    Nonaka, Takahiro
    Maeda, Makoto
    Sugii, Narushi
    Hashimoto, Koichi
    Takano, Shingo
    Koyanagi, Tomoyoshi
    Yamada, Masanobu
    Arakawa, Yoshihiro
    Ishikawa, Eiichi
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (03) : 603 - 610
  • [7] Efficacy Endpoints in Phase II Clinical Trials for Meningioma: An Analysis of Recent Clinical Trials
    Shinya Watanabe
    Takahiro Nonaka
    Makoto Maeda
    Narushi Sugii
    Koichi Hashimoto
    Shingo Takano
    Tomoyoshi Koyanagi
    Masanobu Yamada
    Yoshihiro Arakawa
    Eiichi Ishikawa
    Therapeutic Innovation & Regulatory Science, 2023, 57 : 603 - 610
  • [8] Endpoints for Phase III Trials
    van den Bent, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S40 - S40
  • [9] What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials
    Penel, Nicolas
    Ryckewaert, Thomas
    Kramar, Andrew
    BULLETIN DU CANCER, 2014, 101 (04) : E19 - E24
  • [10] A predictive probability interim design for phase ii clinical trials with continuous endpoints
    Liu, Meng
    Dressler, Emily V.
    TRIALS, 2017, 18
12345